Concepedia

Comparison of the effect of native glucagon‐like peptide 1 and dipeptidyl peptidase IV‐resistant analogues on insulin release from rat pancreatic islets

Siegel, Scharf, Gallwitz, Mentlein, Morys‐Wortmann, Fölsch, F. Schmidt

European Journal of Clinical Investigation · 1999 · 25 citations · 25 references

DOI

Abstract

The analogues tested are biologically active and resistant to degradation by dipeptidyl peptidase IV. Their greater metabolic stability may help to realize the potential of GLP-1 analogues in diabetes therapy.

References

25

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations

, , +5

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

, , +11

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

M. Gutniak, Cathrine Ørskov, Jens J. Holst et al. · New England Journal of Medicine · 1992 · 868 citations · Full text

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Carolyn F. Deacon, Anders H. Johnsen, Jens J. Holst · The Journal of Clinical Endocrinology & Metabolism · 1995 · 754 citations

, , +17